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This is a preliminary account of a study to assess any benefit that might result from the use of pimozide in chronic schizophrenic patients characterized by emotional withdrawal and decreased social competence. It aimed to establish whether pimozide as a sole maintenance therapy is useful and beneficial for apathetic, withdrawn schizophrenic patients and the extent to which any re-socialization can be achieved, together with a measure of any changes in side-effects and the rate of relapse.
Patients and Methods
It was interesting that from most wards of a very large psychiatric hospital, it was only possible to obtain 13 in-patients who fulfilled the study criteria. It seems clear therefore that most of these patients are now living outside hospitals, unless there are strong clinical or social reasons to prevent this from happening. These 13 patients had a long-standing confirmed diagnosis of schizophrenia, based on symptoms rather than outcome. They were all currently being maintained on neuroleptic therapy other than pimozide and they were all aged under 60. The latter criterion was the major problem in selecting this group of patients, because the population of the hospital has aged remarkably.
The primary clinical features of selection were apathy, emotional and social withdrawal and lack of motivation. No patients were selected who had had a history of aggressive outbursts, nor in whom there was any possible physical contra-indication.
The method was to stop all medication for 1 month before beginning the use of pimozide. However, if during this drug-free interval the patient showed any clinical signs of relapse, pimozide was started at that point, without waiting for the end of the month. The starting dose was 8 mg daily in a single dose and this was increased, adding 4 mg/day weekly, to a maximum dose of 20 mg. The Present State Examination was carried out at the point where previous medication was withdrawn and at monthly intervals patients are being assessed on the BPRS. They are also rated on Cheadle's St Wulstan's Ward Behaviour Scale (Cheadle 1975) . Side-effects have been rated on the Simpson & Angus (1970) scale and those occupied in indus-trial or occupational therapy were also rated on the Work Report of Cheadle & Morgan (1972) .
The only other medication that has been given during the period on pimozide has been benzhexol for those who have required it, such administration being recorded.
Results
One patient had to be withdrawn from the trial because of aggressive behaviour, being threatening to other patients and staff. This happened after 5 weeks of pimozide therapy. The progress of the remaining 12 patients is given in Table 1 . There was a dramatic change for the better in the case of 1 patient, but in the other cases the change so far has not been remarkable. After the completion of this report, 1 patient who had shown some benefit was found dead in a river near the hospital. There had been no overt indication of depression before this, although he had shown a higher level of activity than for a long time. One patient showed severe extrapyramidal side-effects, but these were controlled adequately by 10 mg daily of benzhexol. The mean score of side-effects at present is 5, which is at SAGE Publications on June 21, 2016 jrs.sagepub.com Downloaded from mostly shown in the form of mild joint stiffness. Otherwise, the results are as might be expected in a typical chronically handicapped group of mental hospital patients.
At this point the trial is only half complete and it would be wrong to offer any firm conclusions. However, it has shown that 20 mg/day is certainly a feasible dose of pimozide for patients of this kind. It may well be that at least a proportion of these patients (who are really the hard core of the chronically handicapped in mental hospitals) may have some benefit to gain from withdrawal of other neuroleptic therapy and the substitution of pimozide. However, it should not be forgotten that increased activation in patients of this kind may possibly carry with it a certain element of risk, at least for some time.
